Dr. Gilberto Lopes Joins Immorta Bio: A Leap into Longevity and Cancer Treatment
Dr. Gilberto Lopes Joins Immorta Bio: A Leap into Longevity and Cancer Treatment
Introduction
Immorta Bio Inc., an innovative company focusing on scientific longevity, proudly announced the appointment of Dr. Gilberto de Lima Lopes Jr., an eminent figure in lung cancer research, to its Strategic Advisory Board. This move embodies Immorta Bio's commitment to revolutionizing treatment options in the field of aging and cancer therapy.
A Pioneer in Immuno-Oncology
Dr. Lopes is globally recognized for his groundbreaking work in lung cancer, particularly as the principal investigator of the KEYNOTE-042 trial. This pivotal study was integral in the 2019 FDA approval of pembrolizumab (Keytruda®) as a first-line treatment for patients with PD-L1–positive advanced Non-Small Cell Lung Cancer (NSCLC). Thanks to his contributions, hundreds of thousands of patients worldwide have gained greater access to life-saving immunotherapy options.
Boris N. Reznik, PhD, Chairman and CEO of Immorta Bio, expressed his enthusiasm about Dr. Lopes joining the team, stating, “We are honored to welcome a medical pioneer who helped bring game-changing immunotherapy to lung cancer. With Dr. Lopes' guidance, we aim to deliver the next leap—senolytic immunotherapy—to patients who need new options.”
The Focus of Immorta Bio
At the heart of Immorta Bio's mission is their lead program, SenoVax™. This first-in-class senolytic immunotherapy targets the removal of senescent cells—aged, dysfunctional cells that not only accumulate in tumors but also contribute to therapy resistance and immune evasion. By training the immune system to eliminate these unwanted cells, SenoVax™ has exhibited promising anti-tumor activity across various solid tumor models, including lung, breast, glioma, and pancreatic cancers.
Immorta Bio is in collaboration with the FDA to progress SenoVax™ into clinical trials, specifically a Phase I/IIa study focusing on advanced NSCLC.
Dr. Thomas E. Ichim, the President and Chief Scientific Officer of Immorta Bio, commented on the significance of this program: “Our SenoVax™ program shows that removing senescent cells can de-shield tumors and enable immune-mediated destruction. Beyond oncology, targeting senescence has the potential to restore youthful immune and regenerative function, a cornerstone of our longevity vision.”
A Vision for the Future
On his new role, Dr. Lopes stated, “Joining Immorta Bio is an exciting opportunity to extend the promise of immunotherapy beyond traditional cancer care into longevity and healthy aging. The concept behind SenoVax™—targeting senescent cells to enhance anti-tumor immunity—builds on the foundation established by checkpoint inhibitors like pembrolizumab.” His vision aligns perfectly with Immorta Bio’s ethos, focusing on not just treating cancer but enhancing life quality through longevity-focused therapeutic strategies.
About Immorta Bio
Immorta Bio Inc. is at the forefront of developing personalized cellular and immune therapeutics aimed at “Treating Diseases of Aging and Treating Aging as Disease™.” In addition to SenoVax™, they are working on other innovative platforms like StemCellRevivify™ which focuses on personalized cellular rejuvenation. This ongoing research promises to enhance therapeutic options available to patients with advanced NSCLC and beyond.
For more information on Immorta Bio and their initiatives, visit immortabio.com.
Conclusion
The addition of Dr. Gilberto Lopes to Immorta Bio's team signals an influential shift in the fight against cancer, with potential implications for longevity and healthy aging. As researchers and scientists collaborate to innovate within this space, we may witness transformative advancements in the way we approach aging and related diseases.
Media inquiries can be directed to Dr. Boris N. Reznik at Immorta Bio Inc., +1 (305) 632-2939 or via email at [email protected].
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.